Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDLGRO)

Drug Name
Aramchol Drug Info
Synonyms Stearoyl CoA desaturase-1 inhibitor (oral, liver/lipid metabolism diseases), Galmed
Indication
Disease Entry ICD 11 Status REF
Lipid metabolism disorder 5C52.Z Phase 2/3 [1]
Cross-matching ID
PubChem CID
18738120
CAS Number
CAS 246529-22-6
TTD Drug ID
DMDLGRO

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acyl-CoA desaturase (SCD) TT6RIOV ACOD_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Acyl-CoA desaturase (SCD) DTT SCD 7.165 5.49 3.271 6.434
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lipid metabolism disorder
ICD Disease Classification 5C52.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Acyl-CoA desaturase (SCD) DTT SCD 4.73E-01 0.2 0.54
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02279524) A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH. U.S. National Institutes of Health.
2 The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.